News & Updates
Filter by Specialty:

Pegaspargase biosimilar safe to use in childhood ALL
05 Nov 2024
The biosimilar Pegaspargase, when combined with chemotherapy, demonstrates a favourable safety profile in children with acute lymphoid leukemia (ALL) treated according to ICiCLe ALL-14 protocol, a study has shown.
Pegaspargase biosimilar safe to use in childhood ALL
05 Nov 2024
Are SGLT2 inhibitors cardioprotective in wild-type ATTR-CM patients?
05 Nov 2024
byAudrey Abella
The use of sodium glucose cotransporter-2 (SGLT2) inhibitors nearly halves the risk of all-cause mortality at 3 years in patients with wild-type transthyretin amyloid cardiomyopathy (ATTR-CM) and type 2 diabetes (T2D), findings from an observational study suggest.